fortressbio1.jpg
Fortress Biotech to Participate in Three June 2021 Virtual Investor Conferences
June 01, 2021 08:30 ET | Fortress Biotech, Inc.
NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or...
fortressbio1.jpg
Fortress Biotech Announces Webinar Hosted by ROTH Capital Partners Featuring Partner Company Journey Medical Corporation
May 19, 2021 08:00 ET | Fortress Biotech, Inc.
NEW YORK and SCOTTSDALE, Ariz., May 19, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and...
fortressbio1.jpg
REPEAT -- Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
May 17, 2021 07:00 ET | Fortress Biotech, Inc.
Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021 On track to report top-line results from the registration-enabling study of...
fortressbio1.jpg
Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
May 16, 2021 16:00 ET | Fortress Biotech, Inc.
Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021 On track to report top-line results from the registration-enabling study of...
fortressbio1.jpg
Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Europe
May 10, 2021 06:30 ET | Fortress Biotech, Inc.
Agreement signed with Fuji Yakuhin to develop Dotinurad, a potential best-in-class urate transporter (URAT1) inhibitor for gout and potentially other hyperuricemic indications including chronic kidney...
fortressbio1.jpg
Fortress Biotech to Participate in the 20th Annual Needham Virtual Healthcare Conference
April 07, 2021 08:30 ET | Fortress Biotech, Inc.
NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or...
fortressbio1.jpg
Fortress Biotech Reports Record 2020 Financial Results and Recent Corporate Highlights
March 31, 2021 16:15 ET | Fortress Biotech, Inc.
Revenue from marketed dermatology products increased 28% for full-year 2020 compared to 2019 Our partner company, Cyprium Therapeutics, and Sentynl Therapeutics, a wholly-owned subsidiary of the...
Fortress Biotech’s Partner Company, Journey Medical Corporation, In-licenses and Launches Accutane® for the Treatment of Severe Recalcitrant Nodular Acne
March 22, 2021 09:00 ET | Fortress Biotech, Inc.
NEW YORK and SCOTTSDALE, Ariz., March 22, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced that Journey Medical Corporation (“Journey Medical”), a partner...
fortress.jpg
Fortress Biotech to Participate in Four March 2021 Virtual Investor Conferences
March 04, 2021 08:00 ET | Fortress Biotech, Inc.
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or...
fortress.jpg
Fortress Biotech Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®
February 26, 2021 08:00 ET | Fortress Biotech, Inc.
NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or...